Other languages Cassava Sciences, Inc.

Equities

SAVA

US14817C1071

Market Closed - Nasdaq Other stock markets 01:30:00 01/05/2024 am IST			5-day change	1st Jan Change
22.15 ^USD	-0.67%		+7.79%	-1.60%

29/04	North American Morning Briefing : Investors Brace -2-	DJ
25/03	Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam	25/03
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials	25/03
Cassava Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Cassava Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer?s Disease Dementia	07/02
Social Buzz: Wallstreetbets Stocks Mostly Up Premarket; Cassava Sciences Poised to Rise, Tesla to Decline	13/12
Cassava Sciences, Inc. Announces Board Appointments	08/12
Cassava Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer?S Disease	06/11
Cassava Sciences Completes Patient Enrollment in Phase 3 Program of Simufilam in Alzheimer's Disease	06/11
Sector Update: Health Care Stocks Retreating Late Afternoon	26/23/26
Sector Update: Health Care	26/23/26
Cassava Sciences Says MRI Data Suggests Simufilam Not Linked to Amyloid-Related Imaging Abnormalities	25/23/25
Cassava Sciences Says MRI Data Suggests Simufilam Not Linked to Amyloid-Related Imaging Abnormalities	25/23/25
Cassava Sciences, Inc. Announces Positive Safety Findings Based on Interim Magnetic Resonance Imaging Brain Data from Alzheimer's Patients	25/23/25
Sector Update: Health Care Stocks Advance in Late Afternoon	14/23/14
Sector Update: Health Care Stocks Rising Friday Afternoon	13/23/13
Cassava Sciences Refutes 'Egregious Misconduct' Allegations in CUNY Report, Calls Findings 'Illegitimate'; Shares Slump	13/23/13
MORNING BRIEFING - USA/Asien	13/23/13
Cassava Sciences Completes Enrollment of 804 Participants for 12-Month Phase 3 Alzheimer's Trial	03/23/03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cassava Sciences, Inc.

Equities

SAVA

US14817C1071

Other languages

Filters